ROCURONIUM BROMIDE Drug Patent Profile
✉ Email this page to a colleague
When do Rocuronium Bromide patents expire, and what generic alternatives are available?
Rocuronium Bromide is a drug marketed by Caplin, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Hospira, Meitheal, Mylan Institutional, Piramal Critical, Prinston Inc, Sagent Pharms Inc, Sandoz, Tamarang, Teva Pharms, and West Ward Pharm Corp. and is included in fifteen NDAs.
The generic ingredient in ROCURONIUM BROMIDE is rocuronium bromide. There are eleven drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the rocuronium bromide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Rocuronium Bromide
A generic version of ROCURONIUM BROMIDE was approved as rocuronium bromide by HOSPIRA on November 26th, 2008.
Summary for ROCURONIUM BROMIDE
US Patents: | 0 |
Applicants: | 15 |
NDAs: | 15 |
Finished Product Suppliers / Packagers: | 22 |
Raw Ingredient (Bulk) Api Vendors: | 75 |
Clinical Trials: | 57 |
Patent Applications: | 605 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ROCURONIUM BROMIDE at DailyMed |
Recent Clinical Trials for ROCURONIUM BROMIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Chosun University Hospital | N/A |
Assiut University | Phase 2/Phase 3 |
Yangzhou University | N/A |
Pharmacology for ROCURONIUM BROMIDE
Drug Class | Nondepolarizing Neuromuscular Blocker |
Physiological Effect | Neuromuscular Nondepolarizing Blockade |